Skip to main content
SpringerLink
Log in

Adverse-effect profiles of bisphosphonates are largely determined by their route of administration

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonate for the treatment of osteoporosis. Drug Saf 2007; 30(9): 755–63

    Article  PubMed  CAS  Google Scholar 

  2. Liberman UA. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. Drugs Aging 2006; 23(4): 289–98

    Article  PubMed  CAS  Google Scholar 

  3. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 54. London: BMJ Publishing Group Ltd and RPS Publishing, 2007 Sep

  4. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3): 1294–301

    Article  PubMed  CAS  Google Scholar 

  5. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95(11): 3112–7

    Article  PubMed  CAS  Google Scholar 

  6. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4(10): 1377–82

    PubMed  CAS  Google Scholar 

  7. Ste-Marie LG, Sod E, Johnson T, et al. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75(6): 469–76

    Article  PubMed  CAS  Google Scholar 

  8. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12(1): 1–12

    CAS  Google Scholar 

  9. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20(5): 757–64

    Article  PubMed  CAS  Google Scholar 

  10. Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65(5): 654–61

    Article  PubMed  CAS  Google Scholar 

  11. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 2008; 139(1): 23–30

    PubMed  Google Scholar 

  12. Etiminan M, Aminzadeh K, Matthew IR, et al. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008 Apr; 35(4): 691–695

    Google Scholar 

  13. Hewitt R, Lissina A, Green A, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobis-phosphonates is inhibited by statins. Clin Exp Immunol 2005 Jan; 139(1): 101–11.

    Article  PubMed  CAS  Google Scholar 

  14. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced γ, δa-T-cell proliferation and activation in vitro. J Bone Miner Res 2004 Feb; 19(2): 278–88

    Article  PubMed  CAS  Google Scholar 

  15. US Food and Drug Administration. Information on bisphosphonates [online]. Available from URL: http://www.fda.gov [Accessed 2008 Mar 4]

  16. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165(3): 346–7

    PubMed  Google Scholar 

  17. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458–68

    Article  PubMed  CAS  Google Scholar 

  18. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100(12): 2613–21

    Article  PubMed  CAS  Google Scholar 

  19. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346(9): 653–61

    Article  PubMed  CAS  Google Scholar 

  20. Neugebauer G, Koehler W, Akinkunmi L, et al. Influence of peak ibandronic acid concentrations after 6mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man [abstract no. 486]. Proc Annu Meet Am Soc Clin Oncol 2001; 20: 122A

    Google Scholar 

  21. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–22

    Article  PubMed  CAS  Google Scholar 

  22. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008 Apr 28; 168(8): 826–31

    Article  PubMed  CAS  Google Scholar 

  23. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007; 356(18): 1895–6

    Article  PubMed  CAS  Google Scholar 

  24. Sørenson HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008 Apr 12; 336(7648): 813–6

    Article  Google Scholar 

  25. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348(9041): 1535–41

    Article  PubMed  CAS  Google Scholar 

  26. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): 2077–82

    Article  PubMed  CAS  Google Scholar 

  27. US Food and Drug Administration. Early communication of an ongoing safety review: bisphosphonates [online]. Available from URL: http://www.fda.gov [Accessed 2008 Mar 4]

  28. Steinbuch M, D’Agostino R, Mandel J, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 2002; 35(3): 320–6

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adverse-effect profiles of bisphosphonates are largely determined by their route of administration. Drugs Ther. Perspect 24, 23–26 (2008). https://doi.org/10.2165/00042310-200824070-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824070-00007

Search

Navigation